Johnson & Johnson Accelerates Strategic Transformation Through Asset Divestitures and Spin-offs

　　【Pharmaceutical Network Enterprise News] Recently, the surgeryRobotQuantum Surgical Announces Completion of Acquisition of NeuWave Medical, a Developer of Microwave Ablation Technology. Reportedly, NeuWave Medical is a professional provider of interventional oncology solutions in the United States and became Johnson & Johnson's Ethicon microwave ablation technology platform after being acquired by Johnson & Johnson in 2016.
 

It is reported that in September 2025, Johnson & Johnson reached a preliminary agreement with Quantum Surgical on the sale of NeuWave Medical. After the acquisition is completed, Quantum Surgical and NeuWave Medical will operate as subsidiaries of Precision IO Group Inc. Precision IO Group aims to become a leading company in the field of interventional radiology, focusing on precision diagnosis and treatment as well as remote surgery. This acquisition will help the company advance its strategic goals, promote the popularization of robot-assisted tumor ablation therapy, and thereby reduce cancer mortality.
 

Notably, the acquisition of Johnson & Johnson's subsidiary businesses also reflects its acceleration in strategic focus and asset optimization. It is reported that in recent years, the company has carried out a series of strategic adjustments. In addition to selling NeuWave Medical, as early as August 23, 2023, Johnson & Johnson completed its spin-off, with Kenvue fully separating from the parent company to operate independently, focusing on providing innovative medical and consumer health products to patients and consumers worldwide.
 

Johnson & Johnson is still evaluating the spin-off plan of its orthopedic business DePuy Synthes this year. The business may be directly sold at a price exceeding 20 billion US dollars, instead of being split into a separate listing. According to reports, DePuy Synthes is the core orthopedic division under Johnson & Johnson, focusing on the research, development, and production of orthopedic-related devices, covering core products such as hip and knee replacement instruments, with projected sales reaching 9.3 billion US dollars in 2025.
 

As early as October 2025, Johnson & Johnson had announced plans to spin off DePuy Synthes. The plan at that time was to split it into an independent publicly listed company, thereby achieving business focus and concentrating resources on innovative drugs and high-growth medical technology fields.
 

In addition, Johnson & Johnson officially announced at the end of 2025 that it would implement an organizational restructuring, changing the operational approach of its business units. Starting from January 1, 2026, it will shift globally from a regional model to a business unit-led operational model, along with a series of adjustments to its departments and leadership levels, transitioning to a completely new business unit-led structure.
 

In the departmental restructuring, the Surgery and Electrophysiology Business Units will establish independent regional leadership structures. The surgical business will report to Hani Abouhalka, President of the Surgery Business Unit, while the electrophysiology business will report to Michael Bodner, President of the Electrophysiology and Neurovascular Business Unit. The regional supply chain team will also undergo a transformation, led by Luis Roman, Vice President of Medical Technology Supply Chain, and will report to him.
 

It is reported that the restructuring decision was made on the basis of starting to transition to a more decentralized, end-to-end operational model at the beginning of 2024. By granting business units greater autonomy and global responsibility, it aims to stimulate innovation vitality, accelerate product time-to-market, and consolidate its leading position in core market areas.
 

In summary, Johnson & Johnson is transforming from a "medical empire" with a complex business portfolio into a "precise hunter" focused on high-growth, high-technical barrier sectors through a series of decisive asset divestitures / spin-offs. The future Johnson & Johnson will concentrate its resources on fields such as oncology, immunology, neuroscience, cardiovascular, and surgery, where it can create greater value and drive more incremental growth.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.